EP 2532676 B1 20170322 - Protease-regulated antibody
Title (en)
Protease-regulated antibody
Title (de)
Protease-regulierter Antikörper
Title (fr)
Anticorps regulé de protéase
Publication
Application
Previously filed application
PCT/EP2008/006750 20080816 WO
Priority
- EP 08785592 A 20080816
- US 95591307 P 20070815
Abstract (en)
[origin: WO2009021754A2] This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.
IPC 8 full level
C07K 16/00 (2006.01); A61K 47/50 (2017.01); C07K 16/30 (2006.01); C07K 16/36 (2006.01); C07K 16/46 (2006.01)
CPC (source: EP US)
A61K 39/3955 (2013.01 - US); A61K 39/39558 (2013.01 - US); A61K 45/06 (2013.01 - US); A61K 47/6803 (2017.08 - US); A61K 47/6807 (2017.08 - EP US); A61K 47/6809 (2017.08 - EP US); A61K 47/6821 (2017.08 - EP US); A61K 47/6827 (2017.08 - EP US); A61K 47/6829 (2017.08 - EP US); A61K 47/6851 (2017.08 - EP US); A61K 47/6869 (2017.08 - EP US); A61P 1/04 (2018.01 - EP); A61P 1/12 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 5/14 (2018.01 - EP); A61P 7/06 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 31/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 31/06 (2018.01 - EP); A61P 31/14 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 31/20 (2018.01 - EP); A61P 33/06 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 35/02 (2018.01 - EP); A61P 37/02 (2018.01 - EP); C07K 16/3069 (2013.01 - EP US); C07K 16/3076 (2013.01 - EP US); C07K 16/36 (2013.01 - EP US); C07K 16/468 (2013.01 - EP US); A61K 2039/505 (2013.01 - EP US); C07K 2317/31 (2013.01 - EP US); C07K 2317/56 (2013.01 - EP US); C07K 2317/64 (2013.01 - EP US); Y02A 50/30 (2018.01 - EP)
Citation (opposition)
Opponent : Nina Louise WHITE
- WO 2009021754 A2 20090219 - BAYER SCHERING PHARMA AG [DE], et al
- US 95591307 P 20070815
- WO 2009025846 A2 20090226 - UNIV CALIFORNIA [US], et al
- US 95745307 P 20070822
- US 5298608 P 20080513
- WO 2007024715 A2 20070301 - ABBOTT LAB [US], et al
- WO 2004009638 A1 20040129 - ISIS INNOVATION [GB], et al
- WO 0191798 A2 20011206 - UNIV CATHOLIQUE LOUVAIN [BE], et al
- METZ ET AL.: "Bispecific antibody derivatives with restricted 13 September 2012 binding functionalities that are activated by proteolytic processing", PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 25, no. 10, 1 October 2012 (2012-10-01), pages 571 - 580, XP055069821
- DIGIAMMARINO ET AL.: "Ligand association rates to the inner- October 2011 variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design", MABS, vol. 3, no. 5, September 2011 (2011-09-01), pages 487 - 494, XP009168882
- WU ET AL.: "Molecular construction and optimization of July/August 2009 anti-human II-1alpha/beta dual variable domain immunoglobulin ( DVD -Ig) molecules", MABS, vol. 1, no. 4, 2009, pages 339 - 347, XP002657321
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2009021754 A2 20090219; WO 2009021754 A3 20090618; CA 2696263 A1 20090219; CA 2696263 C 20170613; EP 2178914 A2 20100428; EP 2532676 A1 20121212; EP 2532676 B1 20170322; ES 2628395 T3 20170802; JP 2010535832 A 20101125; JP 2014129374 A 20140710; JP 5485152 B2 20140507; JP 5863201 B2 20160216; US 2011229476 A1 20110922; US 2017210825 A1 20170727; US 9624309 B2 20170418
DOCDB simple family (application)
EP 2008006750 W 20080816; CA 2696263 A 20080816; EP 08785592 A 20080816; EP 12172879 A 20080816; ES 12172879 T 20080816; JP 2010520502 A 20080816; JP 2014029811 A 20140219; US 201715466587 A 20170322; US 67194208 A 20080816